ClinicalTrials.Veeva

Menu
F

Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico | Haematology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Guselkumab
Rocatinlimab
GED-0301
Apremilast
Ustekinumab
CC-10004
Nivolumab
Macitentan
Docetaxel
Dexamethasone

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

28 of 49 total trials

A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

This study was created to provide subjects who complete Week 52 (end of Apremilast Extension Phase) of study CC-10004-PPSO-003 the option to continue...

Active, not recruiting
Psoriasis
Drug: Apremilast

A randomized, double-masked, placebo-controlled safety, tolerability and efficacy study of VRDN-001 in participants with chronic thyroid eye disease...

Enrolling
Thyroid Eye Disease
Drug: VRDN-001 10 mg/kg Drug:

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with ep...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Lazertinib
Drug: Amivantamab

The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving dep...

Enrolling
Depressive Disorder, Major
Anhedonia
Drug: Aticaprant
Other: Placebo

The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Pemetrexed
Drug: Amivantamab

The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and to assess the overall safety o...

Enrolling
Perianal Crohns Disease
Fistulizing Crohns Disease
Drug: Guselkumab
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling
Acute Coronary Syndrome
Drug: Milvexian
Other: Placebo

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling
Atrial Fibrillation
Drug: Apixaban Placebo
Drug: Milvexian

The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participan...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Biological: Nivolumab
Drug: Carboplatin

Primary immune thrombocytopenia (ITP) is a rare disease that results in low levels of platelets - the cells that help blood clot.The main aim of the...

Active, not recruiting
Primary Immune Thrombocytopenia
Drug: Placebo
Drug: TAK-079

The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrop...

Enrolling
Multiple System Atrophy
Drug: Placebo
Drug: TAK-341

The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juven...

Enrolling
Arthritis, Juvenile
Drug: Guselkumab
Drug: Ustekinumab

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subje...

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

The study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or...

Enrolling
Eosinophilic Gastrointestinal Disease
Eosinophilic Gastritis
Drug: Dupilumab Dose 2
Drug: Matching Placebo

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA...

Active, not recruiting
Immunoglobulin A Nephropathy
IgA Nephropathy
Drug: Placebo
Drug: Atrasentan

Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of...

Active, not recruiting
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Drug: Placebo tadalafil
Drug: Macitentan 10 mg

The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical mea...

Enrolling
Parkinson's Disease
Drug: Placebo
Drug: BIA 28-6156 60 mg

Trial sponsors

Amgen logo
Celgene logo
Janssen (J&J Innovative Medicine) logo
Takeda logo
A
Bristol-Myers Squibb (BMS) logo
Daiichi Sankyo logo
Janssen (J&J Innovative Medicine) logo
Janssen (J&J Innovative Medicine) logo
Actelion Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems